HAND-TO-HANDNCT06639178
Effectiveness of an N-acetylcysteine and Urea-based Cream in Prevention of Capecitabine-induced HAND-foot Syndrome in Breast Cancer Patients
StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor Study title shortened, about 6 wordsv2
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
To evaluate the role of NAC plus urea-based cream (DECLARAN) in the prevention of Capecitabine-induced HFS in patient affected by breast cancer.
Timeframe: up to 2 years
Secondary (5)
To evaluate severe HFS
To evaluate the impact of HFS on patients' quality of life at 6 weeks
To evaluate the impact of HFS on patients' quality of life at 12 weeks
To evaluate the impact of HFS on patients' quality of life at 24 weeks
To evaluate the safety of NAC plus urea-based cream
Arms and interventions
DECLARAN creamExperimental
Patients will apply of DECLARAN cream is the investigational product based on NAC and urea
Other: DECLARAN cream
Sites
2 sites in 1 country